title: Systemic adverse events after bevacizumab.
authors.forename: Daniel B
authors.initials: DB
authors.lastname: Roth
authors.forename: Alex
authors.initials: A
authors.lastname: King
authors.forename: Meredith
authors.initials: M
authors.lastname: Weiss
authors.forename: Daniel
authors.initials: D
authors.lastname: Klein
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced; D006333:Heart Failure / Q000139:chemically induced; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007267:Injections; D008297:Male; D009203:Myocardial Infarction / Q000139:chemically induced; D012164:Retinal Diseases / Q000188:drug therapy; D012189:Retrospective Studies; D020521:Stroke / Q000139:chemically induced; D011795:Surveys and Questionnaires; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab